A Phamacoeconomic Analysis of Personalized Dosing vs Fixed Dosing of Pembrolizumab in Firstline PD-L1-Positive Non–Small Cell Lung CancerDaniel A. Goldstein, Alona Zer, Noa Gordon et al.|JNCI Journal of the National Cancer Institute|2017Cited by 102